Annexon nabs $44 mln in Series B led by NEA

Annexon Biosciences closed a $44 million Series B financing led by new investor New Enterprise Associates. Also participating were Correlation Ventures and existing investors including Novartis Venture Fund, Clarus, and Satter Investment Management, LLC. Annexon is pursuing biopharmaceutical therapies for neurodegenerative disorders.

Source: Press Release